Health Care · Pharmaceutical Preparations

VERA Vera Therapeutics, Inc. SEC Filings & Insider Trading Activity 2026

company
CIK 183182896 filings
Russell 2000

VERA at a glance

Vera Therapeutics, Inc. (VERA, SEC CIK 1831828) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 5, 2026 and Form 4 insider filings as recently as September 17, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • As of September 30, 2026, 27 institutional investment managers tracked by SignalX reported holding Vera Therapeutics, Inc. (VERA) shares worth $710.4 million in 13F-HR filings.
  • The most recent insider open-market sale reported on Form 4 was by Fordyce Marshall on September 15, 2026 of 18,500 shares at $37.00 per share.
  • In the last 90 days, VERA insiders reported 0 open-market purchases ($0) and 2 open-market sales ($1.3M) on Form 4, a net sale of $1.3M.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Insiders · 90 days
0 buys · 2 sells
Net −$1.3M
13F holders
27 funds
$710.4M · −3 vs prior quarter
Latest 8-K
Nov 5, 2026
Item 2.02

AI 10-K Annual Report Analysis

Latest 10-K, fiscal year ended Dec 31, 2025

Full analysis →

Risk Factors

  • Cybersecurity risk exposure from IT systems or third-party partners, potential regulatory investigations, litigation, fines, business disruption, reputational harm
  • Oversight by audit committee and Cybersecurity Risk Management Committee using manual/automated tools and third-party assessments
  • Key operational risk from reliance on specialized cybersecurity personnel with 29 and 28 years’ experience in biotech IT and security
  • Incident response plan escalates incidents to management and board audit committee, ensuring rapid mitigation and remediation
  • Regular management updates and external briefings to monitor and mitigate evolving cybersecurity threats

AI summary of the VERA 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Management Discussion & Analysis

  • Q3 revenue $10.3M, versus $0 YoY, entirely from TRUTAKNA sales
  • Gross margin 68%, based on $10.3M revenue and $3.3M cost of sales
  • Net loss $93.7M vs $80.3M YoY, with operating expenses $106.0M vs $83.9M
  • Cash, equivalents and marketable securities $384.0M vs $714.6M at December 31, 2025
  • Nine-month operating cash outflow $305.9M vs $171.1M, with $9.6M financing inflow and $75.0M debt draw in October 2026
  • Near-term outlook: continued losses and rising R&D, SG&A and capital expenditures, with liquidity expected for at least 12 months

Risk Factors

  • Newly heightened commercialization risk: FDA accelerated approval of TRUTAKNA on July 7, 2026 created post-approval study and commercial execution obligations
  • Regulatory risk: confirmatory eGFR study failure could trigger accelerated-approval withdrawal after approval based on UPCR results
  • Operational risk: limited commercialization experience and newly building sales, market-access, and distribution capabilities
  • Competitive risk: Roche’s GAZYVA received FDA Priority Review in July 2026 for pMN, with a decision expected by November 2026
  • Financial risk: $150.0 million outstanding under the 2025 Loan Agreement as of October 31, 2026, with covenant-related acceleration exposure

AI summary of the VERA 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 5, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Third-quarter results for period ended September 30, 2026, announced November 5, 2026
  • Corporate updates included alongside financial results

Item EX-99.1: Item EX-99.1

  • Q3 launch generated $10.3M product revenue and approximately 700 Patient Start Forms, establishing initial commercial traction for TRUTAKNA
  • ORIGIN 3 showed eGFR decline of 0.6 versus 5.6 mL/min/1.73m²/year placebo, a 5.0 treatment difference and p<0.0001
Filed Sep 15, 2026Full analysis →

Item EX-99.1: Item EX-99.1

  • ORIGIN 3 met all prespecified endpoints in 428 patients, supporting TRUTAKNA’s potential transition from accelerated to full approval
  • eGFR decline through 104 weeks: -0.6 vs -5.6 mL/min/1.73m²/year, a 5.0 treatment effect with p<0.0001

Item 7.01: Regulation FD Disclosure

  • TRUTAKNA met all prespecified endpoints in final ORIGIN 3 efficacy analysis for adults with primary IgA nephropathy
  • Positive Phase 3 data strengthens TRUTAKNA’s regulatory and commercial prospects in a disease with progression risk

Item 8.01: Other Events

  • ORIGIN 3 met all prespecified endpoints in 428 adults with primary IgAN at risk for progression
  • 52-week eGFR decline: 0.1 versus 5.7 mL/min/1.73m², treatment effect 5.6, p<0.0001

Item EX-99.2: Item EX-99.2

  • ORIGIN 3 final results support Vera’s planned sBLA submission in Q4 2026 and potential full FDA approval in 2027
  • TRUTAKNA improved eGFR by 5.6 mL/min/1.73m at 52 weeks versus placebo, supporting kidney-protection claims
Filed Aug 10, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Q2 2026 results for quarter ended June 30, 2026, released August 10, 2026
  • Corporate updates included alongside earnings release

Item EX-99.1: Item EX-99.1

  • FDA accelerated approval and U.S. launch make TRUTAKNA Vera’s first commercial product and establish a potential IgAN growth platform
  • ORIGIN 3 final efficacy analysis expected Q3 2026, with supplemental BLA submission expected Q4 2026 and potential full approval in 2027

AI summaries of VERA 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for VERA

Don't miss the next VERA filing

  • Alerts as it files. A push when VERA files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut VERA, by share count.
  • Ask anything. An AI agent that reads every VERA filing and answers with sources.

VERA alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Fordyce MarshallSellSep 15, 2026$37.00
Fordyce MarshallMSep 15, 2026-
Fordyce MarshallMSep 15, 2026$2.90
Young Joseph RMSep 11, 2026$3.94
Young Joseph RMSep 11, 2026-
Fordyce MarshallMSep 2, 2026$2.90
Fordyce MarshallMSep 2, 2026-
Fordyce MarshallSellSep 2, 2026$35.12

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Operating Income-$102.0M-$167.2M-$315.5M
Net Income-$96.0M-$152.1M-$299.6M
Balance Sheet
Total Assets$175.5M$655.7M$734.7M
Equity-$577.2M$604.5M
ROE--26.4%-49.6%
Per Share
EPS$-2.25$-2.75$-4.66
Cash Flow
Operating CF-$92.2M-$134.7M-$241.1M
CapEx$63K$972K$630K

Source: XBRL data in Vera Therapeutics, Inc. (VERA)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate VERA share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
VERA shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202627$710.4M
Q2 202630$1.20B
Q1 202630$977.2M
Q4 202525$1.27B
Q3 202524$634.0M
Q2 202525$528.0M
Q1 202522$265.0M
Q4 202420$400.8M
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
New Positions
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 203 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

VERA filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
10-QNov 5, 2026Analysis
8-KNov 5, 2026Analysis-
4Sep 17, 2026--
8-KSep 15, 2026Analysis-
4Sep 14, 2026--
4Sep 4, 2026--
4Aug 12, 2026--
4Aug 12, 2026--
4Aug 12, 2026--
8-KAug 10, 2026Analysis-
10-QAug 10, 2026Analysis
SC 13GAug 7, 2026-
4Aug 5, 2026--
8-KJul 9, 2026Analysis-
4Jul 9, 2026--
8-KJul 7, 2026Analysis-
4Jun 24, 2026--
8-KJun 2, 2026Analysis
4May 26, 2026-
4May 26, 2026-
8-KMay 26, 2026Analysis
4May 26, 2026-
4May 26, 2026-
4May 26, 2026-
4May 26, 2026-

Related Health Care companies

All Health Care →

VERA SEC filings: frequently asked questions

Are VERA insiders buying or selling?

In the last 90 days, Vera Therapeutics, Inc. (VERA) officers, directors and 10% owners reported no open-market purchases and 2 open-market sales worth $1.3 million by 1 insider on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.

Which institutions hold VERA stock?

As of September 30, 2026, the largest Vera Therapeutics, Inc. (VERA) holders among the 13F filers tracked by SignalX were BlackRock ($185.0 million), State Street Corp ($106.6 million), T. Rowe Price Group ($88.8 million), Vanguard Capital Management LLC ($87.5 million), Goldman Sachs Group ($45.9 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What are the main risks in VERA's latest 10-K?

In the 10-K filed February 26, 2026, Vera Therapeutics, Inc. (VERA) flagged: Cybersecurity risk exposure from IT systems or third-party partners, potential regulatory investigations, litigation, fines, business disruption, reputational harm. Oversight by audit committee and Cybersecurity Risk Management Committee using manual/automated tools and third-party assessments. (AI summary of the Risk Factors section.)

What did VERA report in its latest 8-K?

Vera Therapeutics, Inc. (VERA) filed an 8-K on November 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Third-quarter results for period ended September 30, 2026, announced November 5, 2026.

What are the latest VERA SEC filings?

Vera Therapeutics, Inc. (VERA) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 5, 2026 and a Form 4 insider filing on September 17, 2026.

What is VERA's SEC CIK number?

Vera Therapeutics, Inc. (VERA)'s SEC Central Index Key (CIK) is 1831828. EDGAR lists every VERA filing under that number.

Ask anything about VERA

The research agent reads VERA's filings, financials, insider trades and 13F holders, then answers with sources.